Levosimendan Tillomed

Levosimendan, the active ingredient in Levosimendan Tillomed, is a calcium sensitizer presented as an intravenous solution for intravenous use. It improves cardiac contractility in patients experiencing acute decompensated heart failure, helping to restore adequate circulation.

GNH USA supplies Levosimendan Tillomed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to strict quality standards and provides reliable logistics for clinical use across multiple regions, offering consistent product availability, regulatory support, and dedicated technical assistance.

Levosimendan is used as an inotropic agent for conditions involving acute heart failure and related low‑output states.

Acute decompensated heart failure: improves cardiac output and relieves symptoms of congestion. Low cardiac output syndrome: enhances contractility and peripheral perfusion in patients with severe ventricular dysfunction. Heart failure awaiting cardiac transplantation: stabilises haemodynamics and supports organ perfusion before transplant surgery.

Levosimendan may be associated with a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Hypotension: reduction in blood pressure, especially after the loading infusion. - Headache: mild to moderate intensity, often transient. - Nausea: occasional gastrointestinal discomfort. - Tachycardia: increased heart rate during infusion.

Serious or Rare Side Effects: - Ventricular arrhythmias: potentially life‑threatening rhythm disturbances. - Myocardial ischemia: reduced coronary blood flow leading to chest pain. - Severe hypotension: profound drop in blood pressure requiring intervention. - Allergic reactions: rash, bronchospasm, or anaphylaxis in susceptible individuals.

When using Levosimendan, clinicians should observe several safety considerations to minimise risk.

Monitor blood pressure: watch for hypotension during and after infusion. Observe cardiac rhythm: detect arrhythmias early, especially in patients with pre‑existing conduction disorders. Adjust dose in renal/hepatic impairment: consider reduced exposure in organ dysfunction. Avoid in severe hypotension: contraindicated when systolic pressure is markedly low. Use with caution after recent myocardial infarction: assess risk of ischemia. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with other medicines, influencing its safety and efficacy.

Major Interactions (Avoid): - Concurrent vasodilators: may cause severe hypotension. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase plasma concentrations. - Other inotropes (e.g., dobutamine): heighten risk of arrhythmias.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt the inotropic effect. - Diuretics: affect intravascular volume and blood pressure. - ACE inhibitors or ARBs: can enhance hypotensive response. - Anticoagulants: monitor for bleeding if vasodilation alters platelet function.